Synthesis and biological evaluation of sphingosine kinase 2 inhibitors with anti-inflammatory activity.


Journal

Archiv der Pharmazie
ISSN: 1521-4184
Titre abrégé: Arch Pharm (Weinheim)
Pays: Germany
ID NLM: 0330167

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 08 10 2018
revised: 28 11 2018
accepted: 05 12 2018
pubmed: 17 1 2019
medline: 14 6 2019
entrez: 17 1 2019
Statut: ppublish

Résumé

The synthesis of inhibitors of SphK2 with novel structural scaffolds is reported. These compounds were designed from a molecular modeling study, in which the molecular interactions stabilizing the different complexes were taken into account. Particularly interesting is that 7-bromo-2-(2-phenylethyl)-2,3,4,5-tetrahydro-1,4-epoxynaphtho[1,2-b]azepine, which is a selective inhibitor of SphK2, does not exert any cytotoxic effects and has a potent anti-inflammatory effect. It was found to inhibit mononuclear cell adhesion to the dysfunctional endothelium with minimal impact on neutrophil-endothelial cell interactions. The information obtained from our theoretical and experimental study can be useful in the search for inhibitors of SphK2 that play a prominent role in different diseases, especially in inflammatory and cardiovascular disorders.

Identifiants

pubmed: 30648282
doi: 10.1002/ardp.201800298
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Azepines 0
Enzyme Inhibitors 0
Epoxy Compounds 0
Phosphotransferases (Alcohol Group Acceptor) EC 2.7.1.-
sphingosine kinase 2, human EC 2.7.1.91

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1800298

Subventions

Organisme : Universidad Nacional de San Luis
Organisme : Colombian Institute for Science and Research
ID : 110265842651
Organisme : CONICET-Argentina
Organisme : Slovak Research and Development Agency
ID : APVV-0516-12
Organisme : SANOFI-AVENTIS Pharma Slovakia
Organisme : Spanish Ministry of Economy and Competiveness
ID : SAF2014-57845R
Organisme : Spanish Ministry of Economy and Competiveness
ID : SAF2017-89714-R
Organisme : Spanish Ministry of Economy and Competiveness
ID : CP15/00150
Organisme : Carlos III Institute of Health (ISCIII)
Organisme : European Regional Development Fund
Organisme : Spanish Ministry of Innovation and Competitiveness

Informations de copyright

© 2019 Deutsche Pharmazeutische Gesellschaft.

Auteurs

Marcela Vettorazzi (M)

Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, Instituto Multidisciplinario de Investigaciones Biológicas (IMIBIO-SL), San Luis, Argentina.

Laura Vila (L)

Department of Pharmacology, University of Valencia, Valencia, Spain.
Institute of Health Research INCLIVA University Clinic Hospital of Valencia, Valencia, Spain.

Santiago Lima (S)

Department of Biology and Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, Virginia.

Lina Acosta (L)

Laboratorio de Síntesis Orgánica, Escuela de Química, Universidad Industrial de Santander, Bucaramanga, Colombia.

Felipe Yépes (F)

Laboratorio de Síntesis Orgánica, Escuela de Química, Universidad Industrial de Santander, Bucaramanga, Colombia.

Alirio Palma (A)

Laboratorio de Síntesis Orgánica, Escuela de Química, Universidad Industrial de Santander, Bucaramanga, Colombia.

Justo Cobo (J)

Inorganic and Organic Department, University of Jaén, Jaén, Spain.

Jan Tengler (J)

Medis International a.s., Bolatice, Czech Republic.

Ivan Malik (I)

Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Comenius University, Bratislava, Slovakia.

Sergio Alvarez (S)

Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, Instituto Multidisciplinario de Investigaciones Biológicas (IMIBIO-SL), San Luis, Argentina.

Patrice Marqués (P)

Department of Pharmacology, University of Valencia, Valencia, Spain.
Institute of Health Research INCLIVA University Clinic Hospital of Valencia, Valencia, Spain.

Nuria Cabedo (N)

Department of Pharmacology, University of Valencia, Valencia, Spain.
Institute of Health Research INCLIVA University Clinic Hospital of Valencia, Valencia, Spain.

María J Sanz (MJ)

Department of Pharmacology, University of Valencia, Valencia, Spain.
Institute of Health Research INCLIVA University Clinic Hospital of Valencia, Valencia, Spain.

Josef Jampilek (J)

Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Comenius University, Bratislava, Slovakia.

Sarah Spiegel (S)

Department of Biology and Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, Virginia.

Ricardo D Enriz (RD)

Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, Instituto Multidisciplinario de Investigaciones Biológicas (IMIBIO-SL), San Luis, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH